Literature DB >> 8894019

Susceptibility of cats to equine morbillivirus.

H A Westbury1, P T Hooper, S L Brouwer, P W Selleck.   

Abstract

OBJECTIVE: To assess the susceptibility of cats to equine morbillivirus (EMV) by direct administration of the virus by subcutaneous, intra-nasal or oral routes, and following exposure to infected cats.
DESIGN: A disease transmission study, with controls, using ten cats. PROCEDURE: Groups of cats were given the virus by the designated methods and assessed for evidence of infection by clinical examination, plus pathological and virological tests.
RESULTS: All cats administered the virus by subcutaneous, intra-nasal or oral routes became infected and developed the disease within 4 to 8 days. One of two cats in contact with affected cats also developed the disease, but two cats kept near to affected cats did not become infected. The virus was isolated from a range of tissues collected from the infected cats, and the lesions observed in affected cats were similar to those previously observed in horses naturally and experimentally infected with the virus.
CONCLUSION: This is the first demonstration that animals can be infected with EMV by non-parenteral means, that the virus can transmit naturally between animals and confirms other reports of the similarity of EMV disease in horses and cats.

Entities:  

Mesh:

Year:  1996        PMID: 8894019     DOI: 10.1111/j.1751-0813.1996.tb14813.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  24 in total

1.  A novel P/V/C gene in a new member of the Paramyxoviridae family, which causes lethal infection in humans, horses, and other animals.

Authors:  L F Wang; W P Michalski; M Yu; L I Pritchard; G Crameri; B Shiell; B T Eaton
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

2.  Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus.

Authors:  Matthew I Bonaparte; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Bruce A Mungall; Kimberly A Bishop; Vidita Choudhry; Dimiter S Dimitrov; Lin-Fa Wang; Bryan T Eaton; Christopher C Broder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-05       Impact factor: 11.205

Review 3.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

4.  Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine.

Authors:  Bruce A Mungall; Deborah Middleton; Gary Crameri; John Bingham; Kim Halpin; Gail Russell; Diane Green; Jennifer McEachern; L Ian Pritchard; Bryan T Eaton; Lin-Fa Wang; Katharine N Bossart; Christopher C Broder
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

Review 5.  Henipavirus outbreaks to antivirals: the current status of potential therapeutics.

Authors:  Christopher C Broder
Journal:  Curr Opin Virol       Date:  2012-03-21       Impact factor: 7.090

6.  Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.

Authors:  Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Andrew C Hickey; Mark A Smith; Yee-Peng Chan; Lin-Fa Wang; Joseph J Mattapallil; Joan B Geisbert; Katharine N Bossart; Christopher C Broder
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

7.  Henipavirus susceptibility to environmental variables.

Authors:  Rhys Fogarty; Kim Halpin; Alex D Hyatt; Peter Daszak; Bruce A Mungall
Journal:  Virus Res       Date:  2007-12-31       Impact factor: 3.303

8.  Landscape Utilisation, Animal Behaviour and Hendra Virus Risk.

Authors:  H E Field; C S Smith; C E de Jong; D Melville; A Broos; N Kung; J Thompson; D K N Dechmann
Journal:  Ecohealth       Date:  2015-09-24       Impact factor: 3.184

Review 9.  Hendra virus.

Authors:  Deborah Middleton
Journal:  Vet Clin North Am Equine Pract       Date:  2014-09-30       Impact factor: 1.792

10.  Targeted strategies for henipavirus therapeutics.

Authors:  Katharine N Bossart; John Bingham; Deborah Middleton
Journal:  Open Virol J       Date:  2007-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.